Drug Profile
Bevacizumab biosimilar - Bionovis/The Instituto Vital Brazil
Latest Information Update: 09 Oct 2023
Price :
$50
*
At a glance
- Originator Bionovis; The Instituto Vital Brazil
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Breast cancer; Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
Most Recent Events
- 09 Oct 2023 Bevacizumab biosimilar is still in clinical development in Breast-cancer (Metastatic disease and Recurrent) in Brazil (IV) (Bionovis pipeline, October 2023)
- 09 Oct 2023 Bevacizumab biosimilar is still in clinical development in Colorectal-cancer (Metastatic disease) in Brazil (IV) (Bionovis pipeline, October 2023)
- 09 Oct 2023 Bevacizumab biosimilar is still in clinical development in Non-small-cell-lung-cancer in Brazil (IV) (Bionovis pipeline, October 2023)